Stem cells for autoimmune disease: what is real, what is early, what to ask.

Most people do not start with a stem cell question. They start with flares, fatigue, pain, medication side effects, or a disease that keeps returning after every new plan. Stem cells, MSCs, and “immune reset” language sit in a hopeful middle: real immunology, some serious clinical medicine, and a cash-pay market that often uses the same words for very different things.¹

For many readers, the search begins long before the search bar. Years of labs, failed switches between biologics, prednisone tapers that never quite stuck, a flare that arrived right after a clean lab report, a clinician who said “the numbers look fine” when nothing about the day felt fine. The biology of immune modulation and the procedures grouped under “stem cell therapy” are not the same thing, and the page below tries to keep them visibly separate.

Two short translations to keep close at hand before going further. MSCs — mesenchymal stromal cells — are a kind of cell sometimes given as an anti-inflammatory infusion. HSCT — hematopoietic stem cell transplantation — is a transplant procedure that uses chemotherapy to deplete and rebuild parts of the immune system. They are very different treatments. Most of what follows hangs on that difference.

The useful question is not can stem cells fix my immune system? It is: which disease, which product, which route, which evidence, under whose oversight. That is the page. Not a prescription, not a warning to stop researching, not a clinic list — just the shape of what is known so far, in plain English.

If you are reading this in a flare, or in the long flat part between flares, take your time with it. The work below is meant to help you ask sharper questions of a rheumatologist, neurologist, or gastroenterologist who knows your case — not to replace that conversation.

What patients are really hoping for.

“Will this help my autoimmune disease?” is a humane question, and a hard one to answer cleanly, because the hopes folded into it are not the same endpoint. A study that moves one of these can be honestly described as helpful and still leave the others untouched. Separating them is most of the work.

• Fewer flares

  Longer gaps between the bad weeks, and bad weeks that do not climb as high. Patient-felt, often the first thing a reader actually means.

• Lower inflammation

  A measurable drop on the blood or stool tests doctors use to track inflammation — a number, not a feeling. Names you may see on a lab report include CRP and ESR on blood work, calprotectin on a stool test in IBD, and disease-specific markers elsewhere.

• Less pain and fatigue

  The day-to-day burden the labs do not always capture. Hard to measure cleanly, easy to confuse with placebo and natural disease cycles.

• Less steroid dependence

  Getting off prednisone, or staying on a lower maintenance dose without the disease coming back. A specific, trackable outcome.

• Fewer biologic failures

  Not needing the next switch when the current biologic stops working. A meaningful endpoint that few cell-therapy studies report directly.

• Remission

  A clinical category, defined differently across MS, lupus, Crohn's, and RA. The word can mean a marker, a symptom score, an MRI, or a year off medication — they are not the same.

• Nerve, joint, or tissue repair

  The hardest hope to evidence honestly. Regrowing what autoimmune damage has taken is a different bar from quieting the inflammation that is still active.

None of these is a worse hope than any other. Clinic marketing tends to talk about one (“remission”, “immune reset”) while citing evidence for another (a short-window inflammatory-marker drop in a single-arm series). The rest of this page tries not to do that.

HSCT vs MSCs vs exosomes — the distinction that matters most.

The first thing to know is that two clinics can use the same stem-cell phrase and mean very different procedures. An infusion in a private clinic and a transplant procedure at a hospital can both end up under “stem cell therapy” in marketing copy, even though they are not the same kind of treatment, do not share the same evidence, and do not carry the same risks.

Three categories live under that umbrella in autoimmune marketing. The breakdown below sorts them by intensity — how much the procedure asks of the immune system and the body — from a lower-intensity infusion at the top to a transplant-level procedure at the bottom. Intensity, evidence, and risk do not move together automatically: the most evidenced option is also the highest-risk one, and the lower-intensity options are not automatically safer once availability is considered.²

1. 01

   Infusion-level

   A cell or cell-product infusion through an IV, or an injection into a joint or near the spine. No chemotherapy, no transplant — but often described using the same words a transplant clinic would use.

   Includes MSC infusions (mesenchymal stromal cells — cells sometimes used in anti-inflammatory infusions), exosome IV protocols, and local injections. Usually marketed as anti-inflammatory or immune-modulating, often sold cash-pay.

   Evidence + risk Most published autoimmune work at this level is small or short-window. Lab numbers are reported more often than flare rate, steroid dose, or disability progression — the outcomes patients actually feel.

2. 02

   Trial-level

   A cell product being formally tested inside a registered clinical trial, under regulator oversight — usually phase II or phase III.

   Includes Studies run by a hospital, a university group, or a biotech, with a defined product, protocol, and trial registration number.

   Evidence + risk Where most of the legitimate scientific interest sits today. A registered trial is a study being run, not proof the product works — and joining a trial is a different thing from buying a cash-pay infusion that uses some of the same vocabulary.

3. 03

   Transplant-level

   A transplant procedure called HSCT (hematopoietic stem cell transplantation), where chemotherapy is used to deplete parts of the existing immune system before the patient's own stem cells are put back to let a new immune system develop.

   Includes Performed at specialist transplant centers, in defined severity groups, often inside trial protocols or formal hospital pathways. Not a cash-pay menu item.

   Evidence + risk The autoimmune-adjacent procedure with the most serious trial record, especially for severe relapsing MS and severe diffuse systemic sclerosis. Also the highest-risk: chemotherapy effects, infection, infertility, and rare but real treatment-related deaths come with the procedure itself.

A clinic that uses the words “stem cell” or “immune reset” to sell a lower-intensity infusion, while quietly borrowing credibility from the transplant-level evidence, is doing the most common move in this market. The useful question to ask on a brochure or a sales call is: which kind of procedure am I being offered?

For the broader site framing on what is actually in the syringe across the wider regenerative-medicine market, see stem cells vs PRP vs exosomes vs BMAC.

Which autoimmune diseases are being studied.

Autoimmune disease is not one disease, and what counts as evidence shifts a lot between conditions. The list below names six places the research is most active. For each: what the disease is, what is currently being studied, and what a careful reader still needs the data to show.³

Other autoimmune and immune-mediated conditions appear in registered cell-therapy studies as well — autoimmune neurological disorders, autoimmune hepatitis, refractory cytopenias, and others — usually in single trials or small programs. CellDecide treats those as worth watching, not yet worth recommending. For the regulatory framing applied to each named intervention, see methodology.

What the human evidence can and cannot say yet.

The autoimmune cell-therapy literature is real, growing, and uneven. A patient who reads it honestly will find a few patterns worth keeping in mind, rather than a single number that settles things.⁴

• Some evidence is stronger than others. Autologous HSCT for severe relapsing MS and severe diffuse systemic sclerosis has the most developed trial record of any autoimmune cell-based procedure, with recommendations from transplant societies in defined patient groups. Broad cash-pay MSC infusions for general autoimmune indications do not share that evidence base, regardless of overlapping vocabulary.
• Outcomes differ by disease. Relapse rate, MRI lesion activity, disability progression, skin score, organ function, steroid dose, inflammatory markers, fistula closure, drug-free remission, and quality of life are different endpoints. A signal on one does not transfer to another without being demonstrated.
• Risk differs sharply by route and intensity. A conditioning chemotherapy regimen is a different risk category from a peripheral cell infusion, and both are different from a local injection. Risk and evidence-strength do not move in opposite directions automatically — the highest-evidenced procedures on this page are also the highest-risk ones.
• “Immune reset” is not one thing. A conditioning-based transplant procedure that depletes and rebuilds parts of the immune system is genuinely different from a peripheral MSC infusion intended to modulate inflammation. The phrase is not a synonym for either; it is marketing copy that fits over both.
• Comparator matters. Modern autoimmune care is no longer a low bar. Trials that compare a cell product against placebo without using a current biologic or disease-modifying drug as the active comparator are easier to win and harder to translate into treatment decisions.
• The field is interesting because the biology is. Immune modulation, T-cell exhaustion, regulatory-T-cell signaling, and conditioning-based immune reconstitution are real questions in real biology, and they are being studied for that reason. That is a real reason to follow the science. It is not a reason to convert early findings into a treatment narrative.

For the broader site framing on how we read evidence at different strengths, see how to read stem cell evidence without getting lost.

FDA, overseas clinics, and the global reality.

In the United States, no MSC or exosome product is FDA-approved for autoimmune disease. The agency has issued consumer alerts and enforcement actions on direct-to-consumer regenerative offerings — including ones marketed for autoimmune indications — and runs its approval process at the level of specific products for specific indications, not at the level of the broader category. FDA non-approval, on its own, does not mean the underlying biology is worthless. It means the U.S. agency has not licensed the product for the autoimmune use being marketed.⁵

HSCT is a different story. As a transplant procedure, it is performed at U.S. transplant centers in defined patient groups, often inside formal pathways or trial protocols rather than as a cash-pay menu item — and recommendations from groups like EBMT (the European Society for Blood and Marrow Transplantation) describe specific severity groups where the trade-off has been judged reasonable.⁶

Abroad, the same procedures appear under several different combinations: inside hospital-based protocols at tertiary transplant centers; inside registered clinical-study protocols with ethics-committee oversight; under national-regulator authorizations, full or conditional, for specific products and indications (for example, a locally authorized MSC product for perianal fistulas in Crohn’s in parts of Europe); or as cash-pay offerings in private clinics outside any specific authorization for the autoimmune use being treated. All four exist in the market. Availability is not approval, approval is not proof, and FDA non-approval is not a global verdict — but a private cash-pay offering with no named regulator, hospital pathway, or trial behind it is only a claim in the market, not evidence.

The useful question, on either side of the border, is: who oversees this exact product, for this exact autoimmune indication, in this exact setting? A clinic that can name the regulator, the pathway, and the protocol is doing the work. A clinic that gestures at “legal here” or “approved internationally” without naming what or who has not. For travel-side framing specifically, see what to know before traveling.

The promises patients should be careful with.

None of what follows is a judgment of the reader. Being tired of flares, of side effects, of the next switch in a long line of treatments, is the most reasonable thing in the world. The phrases below are not bad because hope is bad. They are bad because they are doing more work than the evidence supports, and they tend to appear in the same conversations that lead to five-figure deposits.

• “Cures autoimmune disease.”
• “Resets your immune system safely.”
• “Works for all autoimmune conditions.”
• “Replaces biologics and steroids.”
• “Permanent remission.”
• “No risk, because it uses your own cells.”

Any of these in a brochure or on a call is a reason to slow down — not necessarily to walk away, but to ask for the exact product, the exact study, the exact patient group, and the exact outcome that was measured. The broader pattern catalog, with what to say in their place, lives at stem cell clinic red flags.

Before you pay: autoimmune-specific questions.

If you searched “stem cells for autoimmune disease near me” or “MS HSCT clinic abroad,” treat that as the start of a screening process, not the end of one. The list below is ten questions to bring to a consult or a phone call, written so the answers belong in writing. A clinic doing this work carefully will have most of these documents ready and will not mind you taking the answers home before deciding.

1. 01

   Which specific disease and severity is this for, and how does my diagnosis fit?

2. 02

   Is this HSCT, MSCs, exosomes, PRP, or something else entirely? What is in the syringe or the bag?

3. 03

   Is the treatment autologous (from me) or from a donor source — and which named source, manufactured under which standard?

4. 04

   Is immune ablation or chemotherapy involved at any stage, and what is the conditioning regimen?

5. 05

   What outcome is being measured: flare rate, steroid dose, MRI lesions, inflammatory markers, disability score, pain or fatigue, remission, surgery avoidance?

6. 06

   What human study supports this exact product for this exact disease and route — and is the citation a published trial or a clinic claim?

7. 07

   What safety monitoring is in place during and after treatment — infection, blood counts, organ function, neurologic signs, thrombosis?

8. 08

   Who manages a flare, an infection, a thrombotic event, or an immunosuppression complication if it happens after I have flown home?

9. 09

   How does this interact with my rheumatologist, neurologist, or gastroenterologist? Will my treating specialist be looped in before and after?

10. 10

    What is included in the quote — procedure only, screening and labs, conditioning, post-treatment monitoring, complication coverage, repeat dosing?

The longer pre-consult list — product identity, condition fit, evidence, oversight, procedure and safety, follow-up, cost — is at questions to ask a stem cell clinic before you pay.

On autoimmune stem cell therapy cost specifically: there is no single number, because the same phrase can be quoted as an MSC infusion in a private clinic, an HSCT procedure at a transplant center, a packaged program with screening and conditioning, or care abroad with travel folded in. Ask for line items, not the headline. CellDecide’s current cost surfaces — what you are really paying for and the total-landed-cost estimator — describe the structure of the bill rather than an autoimmune-specific quote. Use them to plan around the categories; then ask your clinic to fill in the autoimmune-specific numbers in writing.

Common questions.

Short answers to the questions readers most often arrive with. The longer answers live in the sections above.

Can stem cells help autoimmune disease?

Sometimes, in specific diseases, with specific procedures — and almost never as a simple yes. HSCT (a transplant procedure that uses chemotherapy to reset parts of the immune system) has a real trial record in severe relapsing MS and severe diffuse systemic sclerosis. Cash-pay MSC infusions sold for general autoimmune disease sit much earlier on the evidence.

What is HSCT for autoimmune disease?

HSCT is a transplant procedure, not an infusion. Doctors collect the patient’s own blood-forming stem cells, then use chemotherapy to deplete the existing immune system, then put the cells back to let a new immune system develop. It is used in defined severity groups, mostly at transplant centers, primarily for severe MS or systemic sclerosis — and the risk profile (chemotherapy effects, infection, infertility, rare treatment-related deaths) belongs on the same page as the benefit.

Are MSCs the same as immune reset?

No. MSC infusions (mesenchymal stromal cells) are usually marketed as anti-inflammatory or immune-modulating, and may or may not change inflammatory markers. They do not, on their own, perform an immune reset — that phrase usually describes HSCT or a similar conditioning-based procedure that depletes and rebuilds parts of the immune system.

Is stem cell therapy for MS or lupus approved?

Not as a general indication. In the U.S., no MSC infusion is FDA-approved for MS, lupus, or other autoimmune disease, and the FDA has issued specific consumer alerts on direct-to-consumer regenerative offerings. HSCT is performed at U.S. transplant centers in defined patient groups, generally inside trial or specialist pathways rather than as a cash-pay menu item.

Is autoimmune stem cell therapy available outside the U.S.?

Yes — under several different categories that are not equivalent. A registered clinical trial, a hospital transplant pathway, a national-regulator authorization for a specific product, and a private cash-pay clinic offering are four different things. “Available abroad” does not, on its own, mean the procedure is proven for the autoimmune use being marketed.

Where to go from here.

Four next steps for a reader still doing the work before a consult. The product field guide for the words in the brochure; the question list for the call itself; the red-flag patterns to watch for; and the cost write-up for the conversation about money.

What is actually in the syringe — a product field guide →

Questions to ask a stem cell clinic before you pay →

Stem cell clinic red flags →

Stem cell therapy cost: what you are really paying for →

Trust and context total-landed-cost estimator · what to know before traveling · how to read stem cell evidence · methodology · sources · disclosures.